Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 251

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 251
---
 in the form of uncompensated services and loans bearing interest at interest rates DiamiR believes to be below
market value. DiamiR recorded discounts on founder notes payable of $35,063 and $101,221 in the years ended May 31, 2024 and 2023, respectively,
and $24,970 in the nine months ended February 28, 2025 as additional paid-in capital. DiamiR also recorded expenses of $0 and $18,348
for the estimated value of uncompensated services in the years ended May 31, 2024 and 2023, respectively, and $0 in the nine months ended
February 28, 2025 as additional paid-in capital.

<div align='center'>129</div>

Grants Received from Government Agencies

Research and development grants
received from government institutions are recognized as revenue as related research obligations are performed, with qualified expenses
classified as expenses. If grant funds are received in advance of performance, they are initially recognized as liabilities, to the extent
they are refundable.

Since inception, DiamiR has raised over $9.7 million grant funding
from government agencies and disease foundations. On October 1, 2020, DiamiR announced that it received two grants from the National Institutes
of Health (NIH) in the total amount of approximately $3.86 million. The National Institute on Aging (NIA) awarded the company approximately
$3.36 million in a Commercialization Readiness Pilot (CRP) grant as part of its Small Business Innovation Research (SBIR) program. The
award builds upon earlier studies conducted by DiamiR in collaboration with leading academic centers and continues to support development
of CogniMIR, the company’s lead diagnostic product candidate for early detection and monitoring of mild cognitive
impairment and AD. The second award of $498,572 was granted to DiamiR by the National Institute for Neurological Disorders and Stroke
(NINDS) for a project entitled “Circulating Organ-enriched microRNAs as biomarkers of Rett Syndrome.”

Stock-based compensation

Stock-based compensation for
acquiring goods or providing services is recognized at fair value when the goods are obtained or over the service period. If the award
contains performance conditions, the measurement date of the award is the earlier of the date at which a commitment for performance by
the non-employee is reached or the date at which performance is reached. A performance commitment